Generic name:amivantamab-vmjw
Dosage form: injection, for intravenous use
Drug class:Miscellaneous antineoplastics
What is Rybrevant?
Rybrevant is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:
- has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
- has a certain abnormal epidermal growth factor receptor “EGFR” gene(s) and
- whose disease has worsened while on or after chemotherapy that contains platinum.
Your healthcare provider will perform a test to make sure that Rybrevant is right for you.
It is not known if this medicine is safe and effective in children.
Before you receive Rybrevant
Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:
- have a history of lung or breathing problems
- are pregnant or plan to become pregnant. Rybrevant can harm your unborn baby.
Females who are able to become pregnant:- Your healthcare provider should do a pregnancy test before you start treatment.
- You should use effective birth control (contraception) during treatment and for 3 months after your final dose.
- Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment.
- are breastfeeding or plan to breastfeed. It is not known if Rybrevant passes into your breast milk. Do not breastfeed during treatment and for 3 months after your final dose.
Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements.
How will I receive Rybrevant?
- Rybrevant will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between dos
